Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide

(2017) Jian L. Campian et al.   JOURNAL OF NEURO-ONCOLOGY

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013

(2016) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

(2016) D. Mathios et al.   Science Translational Medicine

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

(2016) Mira A. Patel et al.   Journal for ImmunoTherapy of Cancer

Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

(2015) Dimitrios Mathios et al.   INTERNATIONAL JOURNAL OF CANCER

Immunosuppressive mechanisms in glioblastoma: Fig. 1.

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

(2015) Ruea-Yea Huang et al.   Oncotarget

Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo

(2014) Nicholas M. Durham et al.   PLoS One

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH